Multiple Myeloma Research Foundation Launches Investment Fund to Advance New Therapies
Posted: Friday, May 3, 2019
The Multiple Myeloma Research Foundation (MMRF) recently announced that it is launching the Myeloma Investment Fund dedicated to advancing new therapies for patients. The Fund is an independent, self-sustaining vehicle, reportedly the first and largest fund specifically focused in multiple myeloma. The MMRF is building upon its leadership in genomics to leverage opportunities in immunology and further its mission to deliver precision medicine approaches to every patient.
The Myeloma Investment Fund will invest in companies, immunotherapy clinical assets, and technologies with the goal of creating a self-sustaining entity that will reinvest returns to support further myeloma research, decrease a reliance on philanthropy, and maximize donor gifts.
“We created the Myeloma Investment Fund to leverage the MMRF’s formidable assets and advance new therapies for our patients—while generating a return to reinvest in even more research. The Fund will partner with and invest in world-class biotech companies so myeloma patients can benefit from the tremendous progress that is happening in cancer research,” noted Paul Giusti, President and Chief Executive Officer of the MMRF. “It is because of the generosity of our donors, our treasure trove of data, world-class clinical network, deep relationships, and extensive patient engagement that we are able to bring this fund to fruition.”
